Cytotoxic and Anti-proliferative Effects of Ethanol Extract of Marine Sponge Stylissa carteri on Colon Cancer HCT-116 Cell Line
Abstract
Colorectal cancer is one of the most diagnosed cancers in the world. KRAS mutations in colon cancer are being responsible for the progressiveness and resistance of the standard therapeutic available. Marine sponge is one the sources for chemotherapy. Stylissa carteri is a marine sponge that lives in Indonesia and its anti-cancer effects are starting to be explored nowadays. The purpose of this study was to determine the cytotoxicity and anti-proliferative effect of ethanol extract of Stylissa carteri against colon cancer cells with KRAS mutations HCT-116 cells. This was an in vitro study using colon cancer cell line HCT-116 which was tested by 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and trypan blue assay. The trypan blue assay was performed on control and treated cells at 72 h. The MTT assay was performed on cells which were previously incubated with Stylissa carteri extract. Sponge Stylissa carteri was taken from Pramuka island, Taman Nasional Kepulauan Seribu, Jakarta. The IC50 of ethanol extract of Stylissa carteri is 5 μg/mL (R square 0.9550) in HCT-116 cells. The trypan blue assay showed doubling time of incubated cell for 48 h was 26.10 h for control and 39.69 h for treated cells, respectively. Ethanol extract of Stylissa carteri has cytotoxic and anti-proliferative effects in HCT-116 colon cancer cells with KRAS mutation.
Keywords: Colon Cancer, HCT-116, KRAS Mutation, Marine Sponge, Stylissa carteri.
Full Text:
PDFReferences
Ardekani, G.S., Jafarnejad, S.M., Tan, L., Saeedi, A., and Li, G., 2012, The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis, PloS One, 7(10), e47054. CrossRef
Bashari, M.H., Fadhil, M., Aulia, Y., Sari, A.K., Putri, T., Qomarilla, N., et al., 2022, The Ethyl Acetate Fraction of Marine Sponge Stylissa carteri Induces Breast Cancer Cell Death via Upregulation of Mcl-1S: an In vitro Study, Asian Pacific J. Cancer Prev., 23, 1653–1660. CrossRef
Bashari, M.H., Huda, F., Tartila, T.S., Shabrina, S., Putri, T., Qomarilla, N., et al., 2019, Bioactive compounds in the ethanol extract of marine sponge Stylissa carteri demonstrates potential anti-cancer activity in breast cancer cells, Asian Pacific J. Cancer Prev., 20(4), 1199–1206. CrossRef
Dhillon, A.S., Hagan, S., Rath, O., and Kolch, W., 2007, MAP kinase signalling pathways in cancer, Oncogene, 26(22), 3279–3290. CrossRef
Eder, C., Proksch, P., Wray, V., Steube, K., Bringmann, G., van Soest, R.W., et al., 1999, New alkaloids from the Indopacific sponge Stylissa carteri, Journal of Natural Products, 62(1), 184–187. CrossRef
Fouad, M.A., Debbab, A., Wray, V., Müller, W.E.G., and Proksch, P., 2012, New bioactive alkaloids from the marine sponge Stylissa sp, Tetrahedron, 68(49), 10176–10179. CrossRef
Hardani, I.N., Damara, F.A., Nugrahani, A.D., and Bashari, M.H., 2018, Ethanol Extract of Stylissa carteri Induces Cell Death in Parental and Paclitaxel-Resistant Cervical Cancer Cells, Int. J. Integr. Heal. Sci., 6(2), 91–96. CrossRef
Jannah, J.N., Fianza, P.I., Putri, T., and Bashari, M.H., 2019, The ethyl acetate fraction of sponge Stylissa carteri decreases viability in HER2+ trastuzumab-resistant breast cancer cells, J. Kedokteran Dan Kesehatan Indonesia, 10(3), 239–245. CrossRef
Kimman, M., Norman, R., Jan, S., Kingston, D., and Woodward, M., 2012, The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN), Asian Pacific J Cancer Prev, 13(2), 411–420. CrossRef
Labianca, R., Nordlinger, B., Beretta, G.D., Brouquet, A., Cervantes A., and ESMO Guidelines Working Group, 2010, Primary colon cancer : ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up, Ann Oncol., 21(Suppl 5), 70–77. CrossRef
Lee, S.M., Kim, N-H., Lee, S., Kim, Y.N., Heo, J-D., Rho, J-R., and Jeong, E.J., 2019, (10Z)-Debromohymenialdisine from Marine Sponge Stylissa sp. Regulates Intestinal Inflammatory Responses in Co-Culture Model of Epithelial Caco-2 Cells and THP-1 Macrophage Cells, Molecules, 24(18), 3394.
Little, A.S., Balmanno, K., Sale, M.J., Newman, S., Dry, J.R., Hampson, M., et al., 2011, Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells, Sci. Signal, 4(170), er2. CrossRef
Mioso, R., Marante, F.J.T., Bezerra, R.d-S., Borges, F.V.P., Santos, B.V.d-O., and de Laguna, I.H.B., 2017, Cytotoxic Compounds Derived from Marine Sponges. A Review (2010–2012), Molecules, 22(2), 208. CrossRef
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., et al., 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, 486(7404), 532–536. CrossRef
Morrow, C., and Cardenas, P., 2015, Proposal for a revised classification of the Demospongiae (Porifera), Frontiers in Zoology, 12, 7. CrossRef
Quasar Collaborative Group, 2007, Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study, Lancet, 370(9604), 2020–2029. CrossRef
Schmoll, H.J., Cutsem, E.V., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., et al., 2012, ESMO consensus guidelines for management of patients with colon and rectal cancer a personalized approach to clinical decision making, Ann Oncol., 23(10), 2479–516. CrossRef
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA : A Cancer Journal for Clinicians, 71(3), 209-249. CrossRef
Tasdemir, D., Mallon, R., Greenstein, M., Feldberg, L.R., Kim, S.C., Collins, K., et al., 2022, Aldisine Alkaloids from the Philippine Sponge Stylissa massa Are Potent Inhibitors of Mitogen-Activated Protein Kinase Kinase-1 (MEK-1), Journal of Medicinal Chemistry, 45(2), 529–532. CrossRef
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A., 2015, Global Cancer Statistics, 2012, CA Cancer J Clin, 65(2), 87–108. CrossRef
van Krieken, J.H.J.M., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F.T., et al., 2008, KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program, Virchows Archiv, 453(5), 417–431. CrossRef
World Health Organization, 2004, Cytotoxicity: in vitro determination. Geneva. http://who.int/tdr/grants/workplans/en/cytotoxicity_invitro.pdf.
DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev14iss1pp33-38
Copyright (c) 2023 Indonesian Journal of Cancer Chemoprevention
Indexed by:
Indonesian Society for Cancer Chemoprevention
